The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers Meeting Abstract

  

Authors:	Hyman, D. M.; Laetsch, T. W.; Kummar, S.; DuBois, S. G.; Farago, A. F.; Pappo, A. S.; Demetri, G. D.; El-Deiry, W. S.; Lassen, U. N.; Dowlati, A.; Brose, M. S.; Boni, V.; Turpin, B.; Nagasubramanian, R.; Cruickshank, S.; Cox, M. C.; Ku, N. C.; Hawkins, D. S.; Hong, D. S.; Drilon, A. E.
Abstract Title:	The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers
Meeting Title:	53rd Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	35
Issue:	18 Suppl.
Meeting Dates:	2017 Jun 2-6
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2017-06-20
Language:	English
ACCESSION:	WOS:000456827200008
DOI:	10.1200/JCO.2017.35.18_suppl.LBA2501
PROVIDER:	wos
Notes:	Meeting Abstract: LBA2501 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/147167